Related Experiment Videos
Virally inactivated fresh frozen plasma
1Division of Transfusion Medicine, University of Cambridge, UK.
Vox Sanguinis
|January 1, 1995
Summary
Fresh-frozen plasma (FFP) virus inactivation technologies like pasteurization offer viral safety but require efficacy validation. Balancing pooling risks, costs, and licensing is crucial for patient safety.
Area of Science:
- Transfusion Medicine
- Virology
- Biotechnology
Background:
- Fresh-frozen plasma (FFP) is a critical blood product.
- Transfusion-transmitted viral infections remain a concern.
- Several viral inactivation technologies exist for FFP.
Purpose of the Study:
- To review current technologies for inactivating transfusion-transmitted viruses in FFP.
- To discuss the challenges and benefits associated with these FFP treatment methods.
Main Methods:
- Review of existing viral inactivation technologies for FFP: pasteurization, solvent/detergent, and methylene blue/light.
- Analysis of issues including clinical efficacy, viral safety, plasma pooling, licensing, and cost-effectiveness.
Main Results:
- Pasteurization effectively inactivates both enveloped and non-enveloped viruses.
- Solvent/detergent and methylene blue/light methods primarily target enveloped viruses.
- Plasma pooling is required for solvent/detergent and methylene blue/light, unlike pasteurization.
Conclusions:
- Demonstrating clinical efficacy and enhanced viral safety is essential for licensed FFP products.
- Risks of plasma pooling must be weighed against benefits and costs compared to strategies like plasma quarantining.
- Reducing inappropriate FFP use is vital for improving patient safety in transfusion medicine.